Material Event Form 8 K

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On August 14, 2024, NRx Pharmaceuticals, Inc. (the "Company") announced that Stephen Willard, the Company's Chief Executive Officer, ("CEO") has recommended that the Company's shareholders would be best served by a CEO with commercial pharmaceutical experience, particularly drug launch experience, given the Company's upcoming new drug applications for NRX-100 and NRX-101. As a result, the Company has initiated a search for a new CEO possessing the desired qualifications. Mr. Willard will continue to serve as the Company's CEO while this search is initiated.

Mr. Willard has indicated that his recommendation is not the result of any disagreement regarding any matter relating to the Company's operations, policies, or practices.